<DOC>
	<DOCNO>NCT02766582</DOCNO>
	<brief_summary>Phase II single arm , open label , nonrandomized study . The aim study assess Progression Free Survival ( PFS ) suboptimally cytoreduced epithelial ovarian/ primary peritoneal/ fallopian tube cancer patient treat novel combination carboplatin every 21 day ( triweekly ) /weekly paclitaxel IV pembrolizumab IV follow maintenance pembrolizumab IV .</brief_summary>
	<brief_title>Phase II : Pembrolizumab/Carboplatin/Taxol Epithelial Ovary Cancer</brief_title>
	<detailed_description>Utilization combination standard intravenous chemotherapy intravenous pembrolizumab ( 6 cycle ) first line treatment patient advanced ovarian cancer post surgery residual disease . This follow single agent intravenous pembrolizumab ( every 3 week ) 12 additional cycle .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Have advance stage III/IV epithelial ovarian , fallopian tube primary peritoneal cancer Be willing able provide write informed consent/assent trial . Be 18 year age day sign informed consent . Have measurable/ macroscopic disease base RECIST 1.1 . Be willing provide tissue newly obtain core excisional biopsy tumor lesion . Newlyobtained defined specimen obtain 6 week ( 42 day ) prior initiation treatment Day 1 . Subjects newlyobtained sample provide ( e.g . inaccessible subject safety concern ) may submit archived specimen upon agreement Sponsor . Have performance status 0 , 1 2 ECOG Performance Scale . Demonstrate adequate organ function All screening lab perform within 10 day treatment initiation . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Has know history active TB ( Bacillus Tuberculosis ) Hypersensitivity pembrolizumab excipients . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . oNote : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . Has know additional malignancy within last 3 year , progress require active treatment . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Has know history , evidence active , noninfectious pneumonitis . Has active infection require systemic therapy . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Patients medical history condition otherwise previously specify opinion investigator exclude participation study . The investigator consult Study Chair . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Is pregnant breastfeeding , expect conceive child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . Patients borderline ovarian tumor , recurrent epithelial ovarian/ primary peritoneal cancer/fallopian tube cancer nonepithelial ovarian cancer eligible . Has receive live vaccine within 30 day plan start study therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ovarian</keyword>
	<keyword>platinum</keyword>
	<keyword>pembrolizumab</keyword>
</DOC>